Patient-centered, Optimal Integration of Survivorship and Palliative Care

Related Clinical Trial
Patient-centered, Optimal Integration of Survivorship and Palliative Care Immune and Genomic Markers in ALK+ NSCLC Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India An Observational Research Of Crizotinib’s Hepatic Toxicity In Non-small Cell Lung Cancer Patients Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Brief Title

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Official Title

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Brief Summary

      This study is being conducted to develop a supportive care model for patients with metastatic
      Non-small Cell Lung Cancer (NSCLC) to learn to cope with uncertainty and help them understand
      their prognosis and the goal of therapy, in order to live well with cancer.
    

Detailed Description

      This research study involves an intervention consisting of four sessions with palliative care
      specialists who have been additionally trained to evaluate and address the specific
      psychosocial issues and health-promoting behaviors of patients with NSCLC.

      The research study procedures include:

        -  Four 60-minute visits with a trained palliative care clinician

        -  Questionnaires and an exit interview

        -  Chart Review

      It is expected that about 15 participants currently receiving targeted therapy at
      Massachusetts General Hospital for lung cancer will take part in this research study
    


Study Type

Interventional


Primary Outcome

Rate of acceptability at 24 weeks

Secondary Outcome

 Rate of acceptability at 12 weeks

Condition

Stage IV Non-small Cell Lung Cancer

Intervention

POISE

Study Arms / Comparison Groups

 POISE
Description:  The intervention will be a structured palliative care intervention in which patients will meet with a palliative care clinician who has been trained on a manual with specific topics to be covered in each of the four visits:
Three surveys: baseline, 12-week, and 24-week post-enrollment
Four 60-minute visits with a trained palliative care clinician
Semi-structured exit interview
Chart review

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Behavioral

Estimated Enrollment

15

Start Date

September 2021

Completion Date

June 1, 2023

Primary Completion Date

December 1, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Age 18 or older

          -  MGH Cancer Center patient

          -  Within 6 months of diagnosis of metastatic NSCLC with oncogenic driver mutation (EGFR,
             ALK, ROS1, RET)

          -  Receiving targeted therapy

          -  Ability to respond in English or Spanish

        Exclusion Criteria:

          -  Cognitive impairment or serious mental illness that limits ability to provide informed
             consent

          -  Need for urgent palliative care or hospice referral

          -  Pregnant women

          -  Prisoners
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Laura A Petrillo, MD, (617) 724-4000, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT04900935

Organization ID

20-722


Responsible Party

Principal Investigator

Study Sponsor

Massachusetts General Hospital

Collaborators

 American Lung Association

Study Sponsor

Laura A Petrillo, MD, Principal Investigator, Massachusetts General Hospital


Verification Date

May 2021